ArticleBMC chemistry2026
Identification of α-glucosidase inhibitory phytochemicals from Erythrina crista-galli using combined experimental and computational methods.
Article in BMC chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
α-Glucosidase inhibition is an important therapeutic strategy for managing type 2 diabetes. This study aims to identify compounds responsible for the α-glucosidase inhibitory activity of Erythrina crista-galli stem bark extract. The ethanol extract shows strong antioxidant activity and the highest α-glucosidase inhibitory activity among the samples tested. LC-MS/MS analysis tentatively identified 36 flavonoid constituents, which were subsequently evaluated through molecular docking against the crystal structure of isomaltase (PDB ID: 3A4A). When compared with isomaltose, the natural substrate of the enzyme, two compounds exhibited more favorable predicted binding affinities and engaged key catalytic residues within the active site, suggesting their potential to act as competitive inhibitors. Molecular dynamics simulations over 500 ns showed that isovitexin-2''-β-ᴅ-glucopyranoside (17) has the lowest MMGBSA binding energy and stable interactions with catalytic residues. ADMET analysis indicated good solubility, intestinal absorption, limited permeability, and low toxicity for isovitexin-2''-β-ᴅ-glucopyranoside (17). This work provides a scientific foundation for further exploration of E. crista-galli and its constituent flavonoids in the development of nutraceutical or pharmaceutical strategies for diabetes management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.